Drug
Delgocitinib
Delgocitinib: highest development phase Phase 3, developed by LEO Pharma. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Delgocitinib NCT05259722 | Phase 3 | Chronic Hand Eczema |
| Delgocitinib NCT07335588 | Phase 3 | Lichen Sclerosus |
| Delgocitinib NCT04949841 | Phase 3 | Chronic Hand Eczema |
| Delgocitinib NCT05355818 | Phase 3 | Chronic Hand Eczema |
| Delgocitinib NCT07487948 | Phase 2 | Central Centrifugal Cicatricial Alopecia |
| Delgocitinib cream NCT07013201 | Phase 2 | Palmoplantar Pustulosis |
| Delgocitinib NCT05486117 | Phase 1 | Chronic Hand Eczema |
Latest
Follow Delgocitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.